Patent details
EP2994137 Title: TREATMENT OF CANCER WITH NALTREXONE
Basic Information
- Publication number:
- EP2994137
- PCT Application Number:
- GB2014051439
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP147255061
- PCT Publication Number:
- WO2014181131
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- TREATMENT OF CANCER WITH NALTREXONE
- French Title of Invention:
- TRAITEMENT DU CANCER AVEC LA NALTREXONE
- German Title of Invention:
- BEHANDLUNG VON KREBS MIT NALTREXON
- SPC Number:
Dates
- Filing date:
- 12/05/2014
- Grant date:
- 14/12/2022
- EP Publication Date:
- 16/03/2016
- PCT Publication Date:
- 13/11/2014
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 14/12/2022
- EP B1 Publication Date:
- 14/12/2022
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 12/05/2023
- Expiration date:
- 12/05/2034
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 07/12/2022
- Name:
- LDN Pharma Limited
- Address:
- 45 Gresham Street, London EC2V 7BG, United Kingdom (GB)
Inventor
1
- Name:
- ALLEN, Rachel
- Address:
- United Kingdom (GB)
2
- Name:
- DALGLEISH, Angus
- Address:
- United Kingdom (GB)
Priority
- Priority Number:
- 201308440
- Priority Date:
- 10/05/2013
- Priority Country:
- United Kingdom (GB)
Classification
- IPC classification:
- A61K 31/485; A61K 31/593; A61K 45/06; A61P 35/00; A61P 37/02;
Publication
European Patent Bulletin
- Issue number:
- 202250
- Publication date:
- 14/12/2022
- Description:
- Grant (B1)
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|